YBL113C Antibody

What criteria should be used for selecting a reliable YBL113C antibody?

When selecting a YBL113C antibody, researchers should prioritize antibodies that have undergone comprehensive validation with appropriate controls. Evidence from YCharOS and similar antibody characterization initiatives demonstrates that many commercially available antibodies perform poorly in actual applications. For optimal selection, evaluate:

• Presence of genetic control data (ideally knockout validation)

• Application-specific performance data (Western blot, immunoprecipitation, immunofluorescence)

• Renewable antibody options (monoclonal) over polyclonal varieties

• Published literature using the specific antibody for your application

The YCharOS initiative has demonstrated that only antibodies tested against genetic knockout controls can provide reliable evidence of specificity. Their assessment of 614 antibodies showed that many perform poorly across applications, particularly polyclonal antibodies . Therefore, independent validation data should be considered essential rather than optional when selecting a YBL113C antibody.

How should I optimize Western blot protocols for YBL113C detection in yeast samples?

Optimizing Western blot protocols for YBL113C detection requires careful consideration of sample preparation, antibody concentration, and detection methods. For yeast samples specifically:

• Prepare samples using established yeast cell extract methods for Western blot analysis:

  • Harvest yeast cells at appropriate density (mid-log phase recommended)

  • Lyse cells with glass beads in buffer containing protease inhibitors

  • Centrifuge to remove debris

  • Determine protein concentration using BCA assay

• Run samples on SDS-PAGE gels with appropriate percentage (typically 10-12% for mid-sized proteins)

• Transfer proteins to membrane using standard protocols (60-90 minutes at 100V)

• Block membrane in PBS with 5% BSA

• Incubate with diluted primary antibody (typically 1:500 to 1:5000) in PBS with 5% BSA, 0.02% sodium azide overnight at 4°C

• Wash membrane thoroughly in PBS

• Incubate with appropriate secondary antibody

• Develop using chemiluminescence or fluorescence-based detection

Always include wild-type lysate alongside knockout controls when available, as this is the gold standard for antibody validation. YCharOS data indicates that high-performing antibodies should show signal only in the wild-type lane, although multiple bands may represent splice variants or post-translational modifications .

How can I assess antibody specificity for YBL113C protein in yeast models?

Assessing antibody specificity for YBL113C requires implementing multiple controls and validation approaches:

• Genetic validation using knockout or knockdown strains:

  • Use CRISPR-Cas9 or traditional homologous recombination to generate YBL113C knockout strains

  • Compare antibody signal between wild-type and knockout lysates

  • A specific antibody will show signal only in wild-type samples

• Recombinant protein controls:

  • Express and purify recombinant YBL113C protein

  • Use as positive control in Western blots

  • Perform peptide competition assays to confirm epitope specificity

• Cross-validation with orthogonal methods:

  • Compare results from different detection methods (Western blot vs. immunofluorescence)

  • Validate with mass spectrometry following immunoprecipitation

  • Correlate with mRNA expression data

YCharOS data has shown that even antibodies performing well in Western blots may lack specificity in other applications, so application-specific validation is essential . Their analysis of over 800 antibodies revealed that selectivity demonstrated in one application should not be used as evidence of selectivity in another, particularly between Western blot and immunofluorescence or immunoprecipitation .

How do I troubleshoot inconsistent or contradictory YBL113C antibody results between different experimental conditions?

Inconsistent or contradictory results with YBL113C antibodies can stem from multiple factors that require systematic troubleshooting:

• Antibody-specific factors:

  • Batch-to-batch variation (particularly in polyclonal antibodies)

  • Degradation due to improper storage or handling

  • Cross-reactivity with similar epitopes in related proteins

• Sample preparation variations:

  • Different lysis buffers affecting protein conformation

  • Variations in post-translational modifications under different growth conditions

  • Presence of proteases degrading the target protein

• Technical variations:

  • Inconsistent transfer efficiency in Western blots

  • Variations in blocking efficiency

  • Secondary antibody cross-reactivity

Systematic troubleshooting approach:

• Standardize protocols across experiments

• Use recombinant protein as positive control

• Include consistent positive and negative controls in each experiment

• Consider epitope masking due to protein interactions or conformational changes

• Test multiple antibodies targeting different epitopes of YBL113C

The YCharOS initiative found that many antibodies demonstrating inconsistent results were subsequently withdrawn or had their recommended usage altered by vendors . This highlights the importance of thorough validation and the value of using antibodies with extensive characterization data.

How can I analyze contradictory data from different YBL113C antibodies in immunofluorescence experiments?

When faced with contradictory immunofluorescence data from different YBL113C antibodies, implement a structured analytical approach:

• Control-based validation:

  • Compare results with genetic knockout controls

  • YCharOS data shows antibodies performing poorly in immunofluorescence rarely have corroborative data in literature

  • Issues often stem from antibody performance rather than staining protocols

• Epitope accessibility analysis:

  • Different fixation methods may mask or expose different epitopes

  • Compare paraformaldehyde, methanol, and acetone fixation

  • Test detergent permeabilization variations (Triton X-100, saponin, digitonin)

• Subcellular localization reconciliation:

  • Compare to published localization data

  • Implement co-localization with known marker proteins

  • Consider GFP-tagged YBL113C expression as orthogonal validation

• Antibody characterization:

  • Compare polyclonal vs monoclonal antibodies

  • Evaluate different epitope-targeting antibodies

  • Consider using antibodies targeting different regions of YBL113C

YCharOS findings revealed that immunofluorescence performance was generally poor across tested antibodies, with limited correlation between Western blot selectivity and immunofluorescence performance . This suggests that separate validation is essential for each application rather than assuming cross-application reliability.

What is the optimal protocol for YBL113C immunoprecipitation from yeast extracts?

The optimal protocol for YBL113C immunoprecipitation from yeast extracts involves careful consideration of lysis conditions, antibody binding, and washing steps:

• Cell lysis and extract preparation:

  • Harvest yeast cells at mid-log phase

  • Resuspend in lysis buffer (50mM HEPES pH 7.5, 150mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate)

  • Add protease inhibitor cocktail and phosphatase inhibitors if relevant

  • Lyse cells using glass beads with vortexing (8 cycles of 30 seconds vortexing, 30 seconds on ice)

  • Clarify lysate by centrifugation (14,000 × g, 10 minutes, 4°C)

  • Determine protein concentration using BCA assay

• Immunoprecipitation:

  • Pre-clear lysate with Protein A/G beads (1 hour, 4°C)

  • Incubate pre-cleared lysate with YBL113C antibody (2-5μg antibody per 1mg protein lysate)

  • Incubate overnight at 4°C with gentle rotation

  • Add Protein A/G beads and incubate 2-4 hours at 4°C

  • Wash beads 4-5 times with wash buffer (lysis buffer with reduced detergent)

  • Elute bound proteins by boiling in SDS sample buffer or use specific peptide elution

• Analysis:

  • Analyze eluted proteins by SDS-PAGE and Western blot

  • Consider mass spectrometry to identify co-immunoprecipitated proteins

  • Validate specificity using knockout controls

YCharOS data indicates that polyclonal antibodies often perform worse than expected in immunoprecipitation experiments, contradicting the conventional assumption that binding to multiple epitopes confers higher efficiency . Therefore, monoclonal antibodies with validated specificity may be preferable for immunoprecipitation of YBL113C.

How can I adapt yeast surface display techniques to validate YBL113C antibody specificity?

Yeast surface display (YSD) offers a powerful approach for validating YBL113C antibody specificity by expressing the target protein on the yeast cell surface:

• Expression construct design:

  • Create fusion constructs of YBL113C with Aga2p display protein

  • Include appropriate ER targeting sequences for proper folding

  • Add epitope tags (such as FLAG or HA) for detection controls

  • Utilize a GAL1-GAL10 bidirectional promoter system for inducible expression

• Expression and display:

  • Transform construct into Saccharomyces cerevisiae EBY100 strain

  • Cultivate transformed yeast in selective media

  • Induce protein expression with galactose (typically 20 g/L)

  • Confirm surface display using anti-epitope tag antibodies

• Antibody validation:

  • Incubate displayed cells with test antibody

  • Analyze binding using flow cytometry

  • Compare binding profiles between YBL113C-displaying and control yeast

  • Test multiple antibody concentrations to establish dose-response

• Controls and optimizations:

  • Include ER chaperones (Kar2p, Pdi1p) co-expression to enhance display efficiency

  • Monitor expression levels via qPCR of relevant genes

  • Use both positive controls (epitope tags) and negative controls (non-displaying yeast)

Research has demonstrated that co-expression of ER chaperones can significantly improve the display efficiency of proteins in yeast surface display systems, as these chaperones facilitate proper protein folding and assembly . Additionally, the use of divergent GAL1-GAL10 promoters allows for simultaneous expression of multiple protein components, which can be advantageous for complex proteins .

What techniques can be used to determine if YBL113C antibodies recognize native versus denatured protein conformations?

Determining whether YBL113C antibodies recognize native versus denatured protein conformations is crucial for selecting appropriate applications:

• Native protein recognition assessment:

  • Immunoprecipitation from non-denaturing lysates

  • Native gel electrophoresis followed by Western blotting

  • Flow cytometry with permeabilized cells

  • Fluorescence anisotropy with purified proteins

  • Surface plasmon resonance (SPR) with purified components

• Denatured protein recognition assessment:

  • Western blot under reducing vs. non-reducing conditions

  • Comparison of different fixation methods in immunofluorescence

  • Limited tryptic digestion followed by antibody binding

  • Peptide array mapping to identify linear epitopes

• Comparative analysis workflow:

  • Express and purify recombinant YBL113C protein

  • Split sample and subject one portion to denaturation

  • Test antibody binding to both native and denatured forms

  • Quantify relative binding affinity in each condition

• Data interpretation:

  • Antibodies recognizing only denatured forms: suitable for Western blot, potentially immunohistochemistry

  • Antibodies recognizing only native forms: ideal for immunoprecipitation, flow cytometry

  • Antibodies recognizing both forms: versatile for multiple applications

Research on conformational epitopes suggests that even minor alterations in protein structure can significantly impact antibody recognition. Limited tryptic digestion studies can provide valuable insights into epitope accessibility and conformation-dependent binding . When testing different antibody applications, it's important to consider that recognition in one application doesn't guarantee performance in another, as demonstrated by YCharOS data showing limited correlation between Western blot and immunofluorescence performance .